Securing rapid market access for proven medtech innovation in the NHS, delivering it efficiently through the various procurement options – and direct to providers in the case of tariff excluded high-risk devices – and getting it reimbursed adequately, comprises perhaps the most challenging of long-term, complex aims for the health care products industry selling into the UK market.
It is a task that has proved consistently tough for medtech manufacturers. In recent years, companies have improved their engagement with UK clinicians and understanding of their needs, but progress...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?